e-ISSN: Pending
Replication FailureOpen accessImmunology and Microbiology· cited by 14

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity

M Lebwohl; Andrew Blauvelt; Cynthia E. Kartman; Cianna Leatherwood; Kenneth B. Gordon; Naveed Sattar; Luis Puig; Joseph F. Merola · 2026 · JAMA Dermatology

WASTE classifies this as Replication Failure · AI classification, approximate

A previously reported effect did not replicate here — verify it holds before you build on it.

Abstract

Importance: Overweight and obesity affect 60% to 78% of patients with psoriasis, affecting disease severity, treatment response, and clinical outcomes. However, no large, randomized, active-controlled clinical trial has evaluated a treatment strategy that addresses both diseases simultaneously. Objective: To evaluate the efficacy and safety of ixekizumab with or without tirzepatide in participants with psoriasis and overweight or obesity. Design, Setting, and Participants: This phase 3b, randomized, open-label, 52-week clinical trial was conducted at 72 sites in the US in adults with moderate

Abstract by M Lebwohl; Andrew Blauvelt; Cynthia E. Kartman; Cianna Leatherwood; Kenneth B. Gordon; Naveed Sattar; Luis Puig; Joseph F. Merola, JAMA Dermatology (2026) — licensed CC BY-SA 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1001/jamadermatol.2026.1753